Sanofi sees positive data in phase 3 tolebrutinib multiple sclerosis study

HJBC/iStock Editorial via Getty Images Sanofi ( NASDAQ: SNY ) said that data from the phase 3 HERCULES study showed that tolebrutinib given to multiple sclerosis patients given slowed disability progression. The BTK inhibitor delayed the time to onset of 6-month confirmed disability progression ( CDP ) by 31% compared to placebo. An.